Who makes 15-methyl prostaglandin F2α?

15-methyl prostaglandin F2α is developed by Brigham and Women's Hospital.

What development phase is 15-methyl prostaglandin F2α in?

15-methyl prostaglandin F2α is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

15-methyl prostaglandin F2α

Brigham and Women's Hospital · FDA-approved active Small molecule Quality 0/100

15-methyl prostaglandin F2α, marketed by Brigham and Women's Hospital, holds a niche position in the pharmaceutical market with a key composition patent expiring in 2028. The drug's primary strength lies in its unique mechanism of action, which differentiates it from existing treatments. The primary risk is the lack of significant revenue data, which may impact its commercial viability post-patent expiry.

At a glance

Generic name	15-methyl prostaglandin F2α
Also known as	Carboprost
Sponsor	Brigham and Women's Hospital
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Second-Line Uterotonics in Postpartum Hemorrhage: A Randomized Clinical Trial (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

15-methyl prostaglandin F2α CI brief — competitive landscape report
15-methyl prostaglandin F2α updates RSS · CI watch RSS
Brigham and Women's Hospital portfolio CI